2024
950-P: Virtual and Self-Guided Omnipod 5 Automated Insulin Delivery (AID) System Onboarding—Real-World Outcomes by Training Type
BERGET C, FORLENZA G, SHERR J, DESALVO D, ALEPPO G, WILMOT E, HUYETT L, HADJIYIANNI I, MENDEZ J, CONROY L, LY T. 950-P: Virtual and Self-Guided Omnipod 5 Automated Insulin Delivery (AID) System Onboarding—Real-World Outcomes by Training Type. Diabetes 2024, 73 DOI: 10.2337/db24-950-p.Peer-Reviewed Original ResearchDigital Gaming and Exercise Among Youth With Type 1 Diabetes: Cross-Sectional Analysis of Data From the Type 1 Diabetes Exercise Initiative Pediatric Study
Patton S, Gal R, Bergford S, Calhoun P, Clements M, Sherr J, Riddell M. Digital Gaming and Exercise Among Youth With Type 1 Diabetes: Cross-Sectional Analysis of Data From the Type 1 Diabetes Exercise Initiative Pediatric Study. JMIR Pediatrics And Parenting 2024, 7: e57198. PMID: 38889077, PMCID: PMC11186795, DOI: 10.2196/57198.Peer-Reviewed Original ResearchExercise sessionsPhysical activityMinutes of physical activityLevels of physical activityRegular physical activityType 1 diabetesCross-sectional analysisDigital gamesHealthy lifestyleActive wearablesGame sessionsExerciseInsulin useNondigital gamesDaily activitiesPediatric studiesSessionsContext of youthDisease statusYouthT1DCharacteristics of digital gamesInsulin pumpObservation periodContinuous glucose monitoringPredicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes
Bergford S, Riddell M, Gal R, Patton S, Clements M, Sherr J, Calhoun P. Predicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics 2024, 26: 728-738. PMID: 38669475, DOI: 10.1089/dia.2024.0061.Peer-Reviewed Original ResearchRepeated measures logistic regressionPhysically active adolescentsHyperglycemia riskType 1 diabetesMeasures logistic regressionComposite riskAcute glucose responseGlucose rateWearing continuous glucose monitoringContinuous glucose monitoringReceiver operating characteristic curveArea under the receiver operating characteristic curveRisk of hypoglycemiaLogistic regressionActive adolescentsHbA1c levelsActivity startExerciseAdolescentsRiskCharacteristic curveHypoglycemiaGlucose responseHyperglycemiaT1DSevere Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-sectional Survey
Sherr J, Laffel L, Liu J, Wolf W, Bispham J, Chapman K, Finan D, Titievsky L, Liu T, Hagan K, Gaglia J, Chandarana K, Bergenstal R, Pettus J. Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-sectional Survey. Diabetes Care 2024, 47: 941-947. PMID: 38295397, PMCID: PMC11116910, DOI: 10.2337/dc23-1765.Peer-Reviewed Original ResearchImpaired awareness of hypoglycemiaSevere hypoglycemic eventsType 1 diabetesGlycemic targetsContinuous glucose monitoringInsulin delivery modalityDiabetes technologyImproved treatment strategiesAwareness of hypoglycemiaImpaired awarenessU.S. RESEARCH DESIGNAdvanced diabetes technologiesProportion of participantsCross-sectional surveySubgroup analysisSevere hypoglycemiaTreatment strategiesAutomated insulin deliveryImpact of continuous glucose monitoringGlycemic metricsHypoglycemic eventsObservational studyProportion of peopleResearch designInsulin deliveryPostprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes
Patton S, Bergford S, Sherr J, Gal R, Calhoun P, Clements M, Riddell M, Martin C. Postprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes. Nutrients 2024, 16: 162. PMID: 38201991, PMCID: PMC10781146, DOI: 10.3390/nu16010162.Peer-Reviewed Original ResearchConceptsGlycemic variabilityGlucose variabilityType 1Continuous glucose monitoringPediatric studiesCarbohydrate intakeDay observation periodMacronutrient intakeDietary guidelinesPhysical activityExercise intensityT1DGlucose monitoringObservation periodTypical mealMeal contentMealIntakeCoefficient of variationAssociationMacronutrient contentMore carbohydratesCliniciansLarge sample
2023
Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12‐Month Follow‐Up Results
Miller K, Bauza C, Kanapka L, Clements M, DeSalvo D, Hood K, Messer L, Sherr J, Bergamo K, Criego A, Freiner E, Lyons S, Monzavi R, Moore W, Prahalad P, Simmons J, Sulik M, Wadwa R, Weinstock R, Willi S, Williams K, Laffel L, Group F. Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12‐Month Follow‐Up Results. Pediatric Diabetes 2023, 2023: 1-12. DOI: 10.1155/2023/6718115.Peer-Reviewed Original ResearchType 1 diabetesMedian percent timeUse of CGMBlood glucose monitoringYoung adultsCGM initiationExtension phaseGlucose monitoringPercent timeContinuous glucose monitoringMean hemoglobinGlycemic controlCGM groupUp ResultsClinical trialsGlycemic outcomesGlycemic benefitsCGM useMonitoring interventionsType 1Further evaluationBGM groupWeeksDlAdultsAdolescent‐ and Young Adult‐Reported Outcomes and Use of Continuous Glucose Monitoring Features: A Report from the CITY Trial
Messer L, Bauza C, Miller K, Clements M, DeSalvo D, Sherr J, Weinstock R, Hood K, Laffel L. Adolescent‐ and Young Adult‐Reported Outcomes and Use of Continuous Glucose Monitoring Features: A Report from the CITY Trial. Pediatric Diabetes 2023, 2023: 1-10. DOI: 10.1155/2023/6906023.Peer-Reviewed Original ResearchPittsburgh Sleep Quality IndexYoung adultsBlood glucose metersAdolescents/young adultsGood glycemic controlSleep Quality IndexDays/weekType 1 diabetesContinuous glucose monitor useUse of CGMContinuous glucose monitoringBenefits of CGMGlycemic controlCGM groupClinical trialsCGM useMedical outcomesBGM groupGlucose monitoringMonitor useWeeksConfidence ScaleEmotional healthGlucose dataAdultsOGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals
Ylescupidez A, Speake C, Pietropaolo S, Wilson D, Steck A, Sherr J, Gaglia J, Bender C, Lord S, Greenbaum C. OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals. The Journal Of Clinical Endocrinology & Metabolism 2023, 109: 57-67. PMID: 37572381, PMCID: PMC10735531, DOI: 10.1210/clinem/dgad472.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringClinical trialsPositive individualsOral glucose tolerance testPrediction of T1DGlucose tolerance testType 1 diabetesCGM dataTrialNet PathwayMultiple autoantibodiesT1D diagnosisTolerance testAncillary studiesContinuous glucose monitoring dataMultivariable modelCGM metricsInsufficient evidenceAcademic centersGlucose monitoring dataHigh discriminative abilityT1D predictionGlucose monitoringCGM measuresCharacteristic curveOGTT898-P: Real-World Glycemic Outcomes of >3,300 Children and Adolescents with Type 1 Diabetes Using the Omnipod 5 Automated Insulin Delivery (AID) System with Cloud-Based Data Management
SHERR J, DESALVO D, HUYETT L, SNOW K, MENDEZ J, HADJIYIANNI I, LY T. 898-P: Real-World Glycemic Outcomes of >3,300 Children and Adolescents with Type 1 Diabetes Using the Omnipod 5 Automated Insulin Delivery (AID) System with Cloud-Based Data Management. Diabetes 2023, 72 DOI: 10.2337/db23-898-p.Peer-Reviewed Original ResearchCloud-based data managementCloud-based data management systemsJuvenile Diabetes Research FoundationType 1 diabetesUploading of dataNational Institutes of HealthData management systemAge groupsEvaluate real-world outcomesContinuous glucose monitoringGlycemic outcomesAutomatic uploadCloud-basedData managementReal worldUsersMedian timePersonalized therapyGlucose targetsManagement systemInstitutes of HealthTime of analysisReal-world outcomesMedtronicSystem useDiabetes Technology Meeting 2022
Huang J, Yeung A, DuBord A, Wolpert H, Jacobs P, Lee W, Drincic A, Spanakis E, Sherr J, Prahalad P, Fleming A, Hsiao V, Kompala T, Lal R, Fayfman M, Ginsberg B, Galindo R, Stuhr A, Chase J, Najafi B, Masharani U, Seley J, Klonoff D. Diabetes Technology Meeting 2022. Journal Of Diabetes Science And Technology 2023, 17: 1085-1120. PMID: 36704821, PMCID: PMC10347991, DOI: 10.1177/19322968221148743.Peer-Reviewed Case Reports and Technical NotesConceptsDiabetes technologyPainful diabetic neuropathyDiabetic foot ulcersSpinal cord stimulationContinuous glucose monitoringElectronic health recordsDiabetic neuropathyFoot ulcersCord stimulationDiabetes careInsulin delivery systemsInsulin pensMeasurement of glucoseGlucose monitor dataGlucose monitoringInsulin deliveryHealth recordsContinuous glucose monitor dataNovel insulinInsulinDelivery systemDigital healthNeuropathyHypoglycemiaUlcers
2022
Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
Sherr JL, Heinemann L, Fleming GA, Bergenstal RM, Bruttomesso D, Hanaire H, Holl RW, Petrie JR, Peters AL, Evans M. Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia 2022, 66: 3-22. PMID: 36198829, PMCID: PMC9534591, DOI: 10.1007/s00125-022-05744-z.Peer-Reviewed Original ResearchConceptsAmerican Diabetes AssociationStudy of DiabetesDiabetes AssociationEuropean AssociationConsensus reportClinical careInsulin pumpInsulin deliveryIntensive insulin therapyType 1 diabetesManagement of diabetesRegulatory approvalContinuous glucose monitoringWorking GroupInsulin therapyInsulin delivery systemsDiabetesGlucose monitoringGlucose dataInternal review processAssociationSensor glucose dataCareReportGroupAutomated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association.
Sherr JL, Heinemann L, Fleming GA, Bergenstal RM, Bruttomesso D, Hanaire H, Holl RW, Petrie JR, Peters AL, Evans M. Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetes Care 2022, 45: 3058-3074. PMID: 36202061, DOI: 10.2337/dci22-0018.Peer-Reviewed Original ResearchConceptsAmerican Diabetes AssociationStudy of DiabetesDiabetes AssociationEuropean AssociationConsensus reportClinical careInsulin pumpInsulin deliveryIntensive insulin therapyType 1 diabetesManagement of diabetesRegulatory approvalContinuous glucose monitoringWorking GroupInsulin therapyInsulin delivery systemsDiabetesGlucose monitoringGlucose dataInternal review processAssociationSensor glucose dataCareReportGroup92-OR: Persistence of Impaired Awareness of Hypoglycemia, Severe Hypoglycemic Events, and Suboptimal Glycemic Control Despite Advanced Diabetes Technologies
PETTUS J, LIU J, TITIEVSKY L, HAGAN K, LIU T, CHANDARANA K, GAGLIA J, WOLF W, BISPHAM J, CHAPMAN K, FINAN D, SHERR J. 92-OR: Persistence of Impaired Awareness of Hypoglycemia, Severe Hypoglycemic Events, and Suboptimal Glycemic Control Despite Advanced Diabetes Technologies. Diabetes 2022, 71 DOI: 10.2337/db22-92-or.Peer-Reviewed Original ResearchImpaired awareness of hypoglycemiaSevere hypoglycemic eventsRate of severe hypoglycemic eventsAwareness of hypoglycemiaGlycemic controlContinuous glucose monitoringHypoglycemic eventsPrevalence of impaired awareness of hypoglycemiaHybrid closed-loop systemProportion of patientsTarget glycemic controlNational Institute of DiabetesSuboptimal glycemic controlDigestive and Kidney DiseasesT1D Exchange RegistryPatient cohortMedical historyKidney diseaseNon-CGM usersSelf-reported medical historyT1D treatment
2020
Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes
Laffel LM, Kanapka LG, Beck RW, Bergamo K, Clements MA, Criego A, DeSalvo DJ, Goland R, Hood K, Liljenquist D, Messer LH, Monzavi R, Mouse TJ, Prahalad P, Sherr J, Simmons JH, Wadwa RP, Weinstock RS, Willi SM, Miller KM. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes. JAMA 2020, 323: 2388-2396. PMID: 32543683, PMCID: PMC7298603, DOI: 10.1001/jama.2020.6940.Peer-Reviewed Original ResearchConceptsType 1 diabetesContinuous glucose monitoringGlycemic controlPatient-reported outcomesGlucose monitoringYoung adultsSecondary outcomesCGM groupHbA1c outcomesEffects of CGMType 1 diabetes exhibitBGM groupRandomized clinical trialsWorse glycemic controlBlood glucose monitoringDiabetic ketoacidosisMean HbA1cUsual careEndocrinology practiceAdverse eventsMonth 6Primary outcomeSevere hypoglycemiaClinical trialsCGM metrics
2012
Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function
Sherr J, Tamborlane WV, Xing D, Tsalikian E, Mauras N, Buckingham B, White NH, Arbelaez AM, Beck RW, Kollman C, Ruedy K, . Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function. Diabetes Care 2012, 35: 817-820. PMID: 22323414, PMCID: PMC3308298, DOI: 10.2337/dc11-2190.Peer-Reviewed Original ResearchConceptsResidual β-cell functionΒ-cell functionSensor glucose levelsLower glucose variabilityType 1 diabetesGlucose levelsContinuous glucose monitoringT1D participantsGlucose variabilityMean sensor glucose levelPeak C-peptide levelsMixed meal tolerance testTarget A1C levelsC-peptide levelsLong-term T1DShort-term groupNondiabetic groupT1D groupA1c levelsT1D patientsLess hyperglycemiaNondiabetic individualsTolerance testInsulin treatmentHypoglycemiaA Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children Aged 4 to <10 Years
Mauras N, Beck R, Xing D, Ruedy K, Buckingham B, Tansey M, White NH, Weinzimer SA, Tamborlane W, Kollman C, . A Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children Aged 4 to <10 Years. Diabetes Care 2012, 35: 204-210. PMID: 22210571, PMCID: PMC3263860, DOI: 10.2337/dc11-1746.Peer-Reviewed Original ResearchConceptsType 1 diabetesContinuous glucose monitoringGlycemic controlPrimary outcomeParental satisfactionReal-time continuous glucose monitoringGlucose monitoringSevere hypoglycemia ratesDays/weekGlucose dataUsual careHypoglycemia ratesSevere hypoglycemiaCGM groupClinical trialsChildren Aged 4Control groupDiabetesHypoglycemiaDay managementAged 4WeeksParental fearYoung childrenChildren
2011
Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes
Tsalikian E, Fox L, Weinzimer S, Buckingham B, White NH, Beck R, Kollman C, Xing D, Ruedy K, Group D. Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. Pediatric Diabetes 2011, 13: 301-307. PMID: 22151826, PMCID: PMC3665108, DOI: 10.1111/j.1399-5448.2011.00837.x.Peer-Reviewed Original ResearchConceptsType 1 diabetesParental satisfactionMultiple daily injectionsContinuous glucose monitoring useYr of ageYoung childrenContinuous glucose monitoringMean HbA1cMean hemoglobinGlycemic controlMonth 6Daily injectionsMean ageSkin reactionsBiochemical hypoglycemiaCGM useGlucose valuesGlucose readingsInsulin pumpHyperglycemic excursionsHyperglycemic rangeGlucose monitoringMonthsWkDiabetes
2009
From pumps to prevention: recent advances in the treatment of type 1 diabetes
Sherr J, Cengiz E, Tamborlane WV. From pumps to prevention: recent advances in the treatment of type 1 diabetes. Drug Discovery Today 2009, 14: 973-981. PMID: 19580883, DOI: 10.1016/j.drudis.2009.06.011.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAutoimmunityBiosensing TechniquesBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Drug Therapy, CombinationGlycated HemoglobinHumansHypoglycemic AgentsImmunologic FactorsInfusion PumpsInsulinInsulin-Secreting CellsPancreas, ArtificialPrimary PreventionTreatment OutcomeConceptsContinuous subcutaneous insulin infusionContinuous glucose monitoringType 1 diabetes mellitusBeta-cell destructionRapid-acting insulinSubcutaneous insulin infusionTreatment of T1DMType 1 diabetesBlood glucose fluctuationsImproved insulin deliveryAutoimmune processDiabetes mellitusPediatric patientsSecondary interventionsTreatment optionsInsulin infusionNew medicationsGlucose fluctuationsGlucose monitoringInsulin deliveryArtificial pancreasPreventionTreatmentInitial studyMellitus